998 resultados para St. Antoine, Theodore J., 1929-
Resumo:
Translation of La tentation de Saint Antoine.
Resumo:
"Sources": p. vii.
Resumo:
Mode of access: Internet.
Resumo:
Wesley Howe, architect. Building built in 1893; purchased by School of Music in 1929. Sold by UM in 1965.
Resumo:
Wesley Howe, architect. Building built in 1893; purchased by School of Music in 1929. Sold by UM in 1965.
Resumo:
Top Row: Isadore Grodsky, Allen Lamont, Samuel Atkins, Edwin Poorman, Arne Erickson, Walter McLellan, Burt Brubaker
2nd Row: st. mngr Richard Gretsch, Dale Seymour, Crawford Felker, Francis Sanderson, Joseph Austin, Booker Brooks, Eddie Tolan
Front Row: Dalton Seymour, George McArthur, John Tarbill, coach Steve Farrell, Wilford Ketz, Glenn Carlson, Ernest Freese
Resumo:
Signatures: a⁶, A-Q¹² , R⁶.
Resumo:
Latin text (46 p.) has caption title: Vita beatissimi papae Gregorii magni antiquissima.
Resumo:
Mode of access: Internet.
Resumo:
Le diocèse de Sherbrooke fut érigé par le Pape Pie IX. La bulle d'érection, datée de Rome le 28 août 1874, confirmait ainsi le voeu de l'épiscopat de la province ecclésiastique de Québec, émis au cinquième concile provincial du 23 mai 1873. Le nouveau diocèse comprenait un démembrement des diocèses de Québec, de St-Hyacinthe et des Trois-Rivières; Québec cédait trois cantons plus une paroisse; St-Hyacinthe, dix-huit cantons; et Trois-Rivières, vingt-quatre. Moins de la moitié de la population de ce territoire était catholique, soit seulement 30,255 sur une population totale de 68,283 habitants, d'après le recensement de 1870. Par une bulle romaine du premier septembre 1874, Antoine Racine, prêtre desservant de l'église Saint-Jean-Baptiste de Québec, était nommé premier évêque du nouveau diocèse. L'évêque élu avait été prévenu quelques jours auparavant par une lettre de Rome. Consacré à Québec, le 18 octobre 1874, des mains de Mgr Elzéar Alexandre Taschereau, archevêque de Québec, Mgr Antoine Racine prit possession du siège de Sherbrooke le 20 du même mois. Pendant dix-neuf ans, soit jusqu'à sa mort survenue le 17 juillet 1893, l'évêque de Sherbrooke conduisit son diocèse avec prudence, le dotant d'institutions stables. Ses nécrologistes et ses biographes le considèrent comme un des principaux artisans de la pénétration catholique et française dans les Cantons de l'Est. […]
Resumo:
Objective - We report the first randomised controlled trial (RCT) using a combination of St. John’s wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety. Methods - Twenty-eight adults with MDD and co-occurring anxiety were recruited for a double-blind RCT. After a placebo run-in of 2 weeks, the trial had a crossover design testing SJW and Kava against placebo over two controlled phases, each of 4 weeks. The primary analyses used intention-to-treat and completer analyses. Results - On both intention-to-treat ( p¼0.047) and completer analyses ( p¼0.003), SJW and Kava gave a significantly greater reduction in self-reported depression on the Beck Depression Inventory (BDI-II) over placebo in the first controlled phase. However, in the crossover phase, a replication of those effects in the delayed medication group did not occur. Nor were there significant effects on anxiety or quality of life. Conclusion - There was some evidence of antidepressant effects using SJW and Kava in a small sample with comorbid anxiety. Possible explanations for the absence of anxiolysis may include a potential interaction with SJW, the presence of depression, or an inadequate dose of Kava.
Resumo:
Background: Mood and anxiety disorders pose significant health burdens on the community. Kava and St John’s wort (SJW) are the most commonly used herbal medicines in the treatment of anxiety and depressive disorders, respectively. Objectives: To conduct a comprehensive review of kava and SJW, to review any evidence of efficacy, mode of action, pharmacokinetics, safety and use in Major Depressive Disorder (MDD), Bipolar Disorder (BP), Seasonal Affective Disorder (SAD), Generalized Anxiety Disorder (GAD), Social Phobia (SP), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), and Post Traumatic Stress Disorder (PTSD). Methods: A systematic review was conducted using the electronic databases MEDLINE, CINAHL, and The Cochrane Library during late 2008. The search criteria involved mood and anxiety disorder search terms in combination with kava, Piper methysticum, kavalactones, St John’s wort, Hypericum perforatum, hypericin and hyperforin. Additional search criteria for safety, pharmacodynamics , and pharmacokinetics was employed. A subsequent forward search was conducted of the papers using Web of Science cited reference search. Results: Current evidence supports the use of SJW in treating mild-moderate depression, and for kava in treatment of generalized anxiety. In respect to the other disorders, only weak preliminary evidence exists for use of SJW in SAD. Currently there is no published human trial on use of kava in affective disorders, or in OCD, PTSD, PD or SP. These disorders constitute potential applications that warrant exploration. Conclusions: Current evidence for herbal medicines in the treatment of depression and anxiety only supports the use of Hypericum perforatum for depression, and Piper methysticum for generalized anxiety.
Resumo:
The burden of rising health care expenditures has created a demand for information regarding the clinical and economic outcomes associated with complementary and alternative medicines. Meta-analyses of randomized controlled trials have found Hypericum perforatum preparations to be superior to placebo and similarly effective as standard antidepressants in the acute treatment of mild to moderate depression. A clear advantage over antidepressants has been demonstrated in terms of the reduced frequency of adverse effects and lower treatment withdrawal rates, low rates of side effects and good compliance, key variables affecting the cost-effectiveness of a given form of therapy. The most important risk associated with use is potential interactions with other drugs, but this may be mitigated by using extracts with low hyperforin content. As the indirect costs of depression are greater than five times direct treatment costs, given the rising cost of pharmaceutical antidepressants, the comparatively low cost of Hypericum perforatum extract makes it worthy of consideration in the economic evaluation of mild to moderate depression treatments.